[go: up one dir, main page]

MX2016012314A - Analagos de apelina ciclicos. - Google Patents

Analagos de apelina ciclicos.

Info

Publication number
MX2016012314A
MX2016012314A MX2016012314A MX2016012314A MX2016012314A MX 2016012314 A MX2016012314 A MX 2016012314A MX 2016012314 A MX2016012314 A MX 2016012314A MX 2016012314 A MX2016012314 A MX 2016012314A MX 2016012314 A MX2016012314 A MX 2016012314A
Authority
MX
Mexico
Prior art keywords
ala
bridge
cyclic apelin
cyclic
lantionin
Prior art date
Application number
MX2016012314A
Other languages
English (en)
Other versions
MX378539B (es
Inventor
Rink Rick
Original Assignee
Lanthiopep Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanthiopep Bv filed Critical Lanthiopep Bv
Publication of MX2016012314A publication Critical patent/MX2016012314A/es
Publication of MX378539B publication Critical patent/MX378539B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of Stepping Motors (AREA)

Abstract

La invención se refiere al campo de la farmacología. En particular, se refiere a nuevos análogos de apelina, y a los usos terapéuticos de los mismos. Se proporciona un análogo de apelina cíclico de la fórmula general X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X 12-X13-X14, que comprende un puente de lantionina de la estructura Ala-S-Ala o un puente de metil-lantionina de la estructura Abu-S-Ala o Ala-S-Abu, y en donde dicho puente de (metil) lantionina es del tamaño i, i+3; i, i+4, i, i+5 o i, i+6.
MX2016012314A 2014-03-25 2015-03-25 Analagos de apelina ciclicos. MX378539B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14161533 2014-03-25
PCT/NL2015/050191 WO2015147641A1 (en) 2014-03-25 2015-03-25 Cyclic apelin analogs

Publications (2)

Publication Number Publication Date
MX2016012314A true MX2016012314A (es) 2016-11-30
MX378539B MX378539B (es) 2025-03-10

Family

ID=50389830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012314A MX378539B (es) 2014-03-25 2015-03-25 Analagos de apelina ciclicos.

Country Status (20)

Country Link
US (1) US20170107257A1 (es)
EP (1) EP3122764B1 (es)
JP (1) JP6740133B2 (es)
KR (1) KR20160135742A (es)
CN (1) CN106170492B (es)
AU (1) AU2015237357B2 (es)
BR (1) BR112016021835A8 (es)
CA (1) CA2941080A1 (es)
DK (1) DK3122764T3 (es)
ES (1) ES2719137T3 (es)
HR (1) HRP20190544T1 (es)
HU (1) HUE042615T2 (es)
IL (1) IL246487A0 (es)
MX (1) MX378539B (es)
PL (1) PL3122764T3 (es)
PT (1) PT3122764T (es)
RU (1) RU2697515C2 (es)
SG (2) SG10201808383UA (es)
WO (1) WO2015147641A1 (es)
ZA (1) ZA201607177B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
GB202016149D0 (en) * 2020-10-12 2020-11-25 Heptares Therapeutics Ltd Cyclic apelin receptor agonists
CN112851788B (zh) * 2021-02-03 2022-11-01 河北省科学院生物研究所 一种羊毛硫肽LichencinA3及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US7101701B2 (en) * 2004-10-08 2006-09-05 The Trustees Of The University Of Pennsylvania Method to reduce contamination when culturing mycobacteria
ATE512158T1 (de) * 2005-08-12 2011-06-15 Oragenics Inc Differenziell geschützte, orthogonale lanthionintechnologie
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US20090233854A1 (en) * 2005-12-20 2009-09-17 Takeda Pharmaceutical Company Limited Novel application of apelin
CA2695487A1 (en) * 2007-08-03 2009-02-12 Sentinella Pharmaceuticals, Inc. ("Sentinella") Genes and proteins for the biosynthesis of the lantibiotic 107891
EP2405008A1 (en) * 2010-07-06 2012-01-11 LanthioPep B.V. Bacterial surface display of thioether-bridge-containing peptides
EP2603586B2 (en) * 2010-08-13 2025-02-26 Miti Biosystems GmbH Modified peptide display
DK2683360T3 (en) 2011-03-11 2016-05-30 Genzyme Corp PEGYLED APELIN AND APPLICATIONS THEREOF
CN103483433B (zh) * 2013-09-10 2015-05-27 中国科学院微生物研究所 一种新型高效的羊毛硫细菌素cerecidin及其应用

Also Published As

Publication number Publication date
PT3122764T (pt) 2019-04-26
IL246487A0 (en) 2016-08-31
EP3122764A1 (en) 2017-02-01
RU2016139223A (ru) 2018-04-26
CA2941080A1 (en) 2015-10-01
KR20160135742A (ko) 2016-11-28
HUE042615T2 (hu) 2019-07-29
RU2697515C2 (ru) 2019-08-15
SG11201605195RA (en) 2016-10-28
US20170107257A1 (en) 2017-04-20
HRP20190544T1 (hr) 2019-05-31
WO2015147641A1 (en) 2015-10-01
SG10201808383UA (en) 2018-10-30
EP3122764B1 (en) 2019-01-16
MX378539B (es) 2025-03-10
AU2015237357A1 (en) 2016-07-07
BR112016021835A8 (pt) 2018-08-28
DK3122764T3 (en) 2019-04-15
ZA201607177B (en) 2019-07-31
PL3122764T3 (pl) 2019-07-31
ES2719137T3 (es) 2019-07-08
CN106170492B (zh) 2020-08-21
JP6740133B2 (ja) 2020-08-12
RU2016139223A3 (es) 2018-10-12
JP2017512760A (ja) 2017-05-25
CN106170492A (zh) 2016-11-30
AU2015237357B2 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
EA201691582A1 (ru) Новые фармацевтические препараты
IL257379A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
MX2017001279A (es) Usos y composiciones de la flagelina.
PL3482124T3 (pl) Sposób wykorzystywania i sposób modernizacji systemu wytwornicy pary
CR20150648A (es) Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CL2018001493A1 (es) Nuevos derivados de fenilo
CR20160459A (es) Nuevos derivados de piridina
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
CR20160448A (es) Nuevos derivados de piridina
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CR20150649A (es) Derivados de nucleósidos 4´-azido,3´-desoxi-3´-fluoro sustituido
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
DOP2016000064A (es) Derivados de fenilalanina sustituidos
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio